Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report

Effectiveness of afatinib after long-term gefitinib treatment for EGFR L858R and S768I compound mutation-positive lung adenocarcinoma: A case report

Afatinib, a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), irreversibly inhibits the pan-human epidermal growth factor receptor (HER) family. It is effective in patients with lung cancer with various EGFR mutations; however, its efficacy in overcoming resist...

Full description

Saved in:
Bibliographic Details
Main Authors: Ayuka Dai-Shinozaki, Jun Sakakibara-Konishi, Kanako C. Hatanaka, Kento Wakabayashi, Naofumi Shinagawa, Yoshihiro Matsuno, Yutaka Hatanaka, Satoshi Konno
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Adenocarcinoma
NSCLC
EGFR L858R/S768I
Afatinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007125000851
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S2213007125000851

Similar Items